DEBBANE RAYMOND 4

What Happened

• Raymond Debbane, a director of Lexicon Pharmaceuticals (LXRX), received two equity awards reported as derivative acquisitions on 2026-05-01. The grants are for 35,714 and 43,478 units, reported at $0.00 per unit (total reported cash value $0). These are not open-market purchases or sales but company-granted awards.

Key Details

• Transaction date: 2026-05-01; Form 4 filed: 2026-05-04 (timely filing).
• Awards: 35,714 and 43,478 derivative securities (total 79,192 units); reported price $0.00.
• Footnotes provided in the filing:
  • F1/F2: One award is a restricted stock unit (RSU) where each RSU converts to one share and vests 100% on the first anniversary of the grant.
  • F3: The other award is an option that vests one-third on each of the first three anniversaries of the grant date.
• Shares owned after the transaction: not specified in the provided excerpt.
• Transaction code: A (award/grant). No indication of tax-withholding sales or a 10b5-1 plan in the excerpt.

Context

• These are company grants (derivative awards), not purchases—RSUs deliver shares if and when vested; options provide the right to buy shares subject to vesting and exercise terms. Such awards are common for directors as compensation and do not by themselves indicate personal buying or selling activity.